Clifton O. Bingham completed a medical degree at Columbia University in New York, where he also completed a residency in internal medicine. He trained as a fellow in rheumatology and allergy/clinical immunology at Brigham and Women’s Hospital in Boston. He subsequently served as attending rheumatologist and allergist/immunologist at Brigham and Women’s Hospital and Massachusetts General Hospital. He was recruited to join the faculty at NYU Hospital for Joint Diseases in 1999, where he directed the rheumatology clinic at Bellevue Hospital Center. At NYU he founded and directed the Seligman Center for Advanced Therapeutics, a pioneering center that incorporated cutting-edge clinical therapeutics with clinical trials and translational research in rheumatology. In 2005, Dr. Bingham was recruited to join the faculty at Johns Hopkins University where he now is an Associate Professor and Director of the Johns Hopkins Arthritis Center. Dr. Bingham currently serves as a member of the Executive Committee for the international Outcome Measures in Rheumatology Clinical Trials (OMERACT) group, and he chairs workstreams developing a standardized definition of disease flares in rheumatoid arthritis and evaluating the efficacy and safety of intraarticular agents, including gene therapy. He has been active in American College of Rheumatology and Arthritis Foundation committees and has chaired meetings, study groups, and grant review sections. Dr. Bingham has served as an investigator for several clinical trials of agents in early to late phases of development for the treatment of rheumatoid arthritis and osteoarthritis. This includes service as lead investigator for the largest international study to date of a disease-modifying drug for osteoarthritis (KOSTAR), the National Institutes of Health–sponsored Glucosamine Arthritis Interventional Trial (GAIT), and a controlled study of immunization responses in patients treated with rituximab (SIERRA). Dr. Bingham has served as lead investigator in more than 35 additional clinical trials for rheumatoid arthritis, osteoarthritis, and other autoimmune diseases. His current research program focuses on oral health in inflammatory arthritis, risk factors for osteoarthritis progression, and defining clinical and biochemical disease phenotypes related to therapeutic responses in rheumatoid arthritis and osteoarthritis. He was recently awarded an American College of Rheumatology “Within Our Reach” grant to study Periodontal Disease in patients with rheumatoid arthritis. He is a Co-Editor for Arthritis and Rheumatism and a regular reviewer for several leading rheumatology journals, and he was formerly Associate Editor for Clinical Care in the Rheumatic Diseases. He has authored more than 55 original articles, reviews, and editorials, 10 book chapters, several topics in UpToDate in Medicine, and more than 70 abstracts.